Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 16/20 | 0.33 |
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185769 | 0.81 | LMNA (0.36) | LMNAHTTF2F10RAB9A | |
| SCHEMBL29427272 | 0.77 | LMNA (0.43) | LMNAHTTRAB9AKDM4ETDP1 | |
| SCHEMBL113414 | 0.77 | LMNA (0.43) | LMNAHTTRAB9AKDM4ETDP1 | |
| SCHEMBL14508590 | 0.73 | F2 (0.32) | LMNAHTTF2F10 | |
| SCHEMBL3476708 | 0.72 | LMNA (0.46) | LMNAHTTRAB9AKDM4ETDP1 | |
| SCHEMBL2616406 | 0.69 | LMNA (0.48) | LMNAHTTRAB9AKDM4ETDP1 | |
| Formic Acid SCHEMBL30297733 | 0.68 | LMNA (0.35) | LMNAHTTF2KDM4ETDP1 | |
| SCHEMBL6640541 | 0.65 | LMNA (0.40) | LMNAHTTRAB9AKDM4ETDP1 | |
| SCHEMBL30630362 | 0.65 | LMNA (0.40) | LMNAHTTRAB9AKDM4ETDP1 | |
| SCHEMBL6640669 | 0.64 | LMNA (0.35) | LMNAHTTKDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026324-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040097730-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097730-A1 | Thrombin inhibitors | F3, F2, SERPINC1 | LMNA 4332/4885HTT 3320/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.